Hyderabad is home to a vibrant and growing pharmaceutical industry, with several major pharma companies headquartered in the city. Here are some of the key players in the Hyderabad pharmaceutical industry:
Download all Hyderabad pharma companies list here Download.
- Dr. Reddy’s Laboratories: Founded in 1984, Dr. Reddy’s Laboratories is one of India’s largest pharmaceutical companies, with a focus on generic drugs and active pharmaceutical ingredients (APIs).
- Aurobindo Pharma: Founded in 1986, Aurobindo Pharma is a vertically integrated pharmaceutical company that produces generic drugs, APIs, and formulations across a range of therapeutic areas.
- Divis Laboratories: Established in 1990, Divis Laboratories specializes in the manufacture of APIs, custom synthesis of new molecules, and development of generic drugs.
- Hetero Drugs: Founded in 1993, Hetero Drugs is a leading global pharmaceutical company that produces a wide range of generic drugs, APIs, and biosimilars.
- Laurus Labs: Established in 2007, Laurus Labs is a research-driven pharmaceutical company that develops and manufactures APIs, intermediates, and formulations for the global market.
- Suven Life Sciences: Founded in 1989, Suven Life Sciences is a biopharmaceutical company that focuses on developing innovative therapies for central nervous system disorders, including Alzheimer’s and Parkinson’s diseases.
- Natco Pharma: Established in 1981, Natco Pharma is a vertically integrated pharmaceutical company that produces APIs, formulations, and biosimilars across a range of therapeutic areas.
- SMS Pharmaceuticals: Founded in 1990, SMS Pharmaceuticals is a leading contract manufacturing organization that specializes in the production of APIs, intermediates, and formulations for the global market.
- Lee Pharma: Established in 1997, Lee Pharma is a research-driven pharmaceutical company that specializes in the development and manufacture of APIs and formulations for the global market.
These are just a few examples of the many Hyderabad pharma companies. The city’s pharmaceutical industry is a key driver of economic growth and innovation and is likely to continue expanding in the coming years.
Hyderabad has emerged as a major center for the global pharmaceutical industry for several reasons:
- Strong academic and research institutions: Hyderabad is home to several leading academic and research institutions, including the Indian Institute of Chemical Technology (IICT), the National Institute of Pharmaceutical Education and Research (NIPER), and the Centre for Cellular and Molecular Biology (CCMB). These institutions provide a strong talent pool of scientists, researchers, and technical experts to the pharmaceutical industry.
- Favorable government policies: The Indian government has implemented several policies to promote the growth of the pharmaceutical industry, including tax incentives, research and development funding, and streamlined regulatory processes. These policies have made it easier for pharmaceutical companies to establish operations in Hyderabad and other parts of India.
- Infrastructure and logistics: Hyderabad has a well-developed infrastructure, including a modern airport, seaport, and road and rail networks, which facilitate the movement of goods and people. Additionally, the city has several industrial parks and special economic zones that are specifically designed to attract pharmaceutical companies and other high-tech industries.
- Cost advantages: India offers significant cost advantages for pharmaceutical companies compared to developed countries like the United States and Europe. Labor and production costs are lower, as are regulatory and compliance costs.
- Proximity to markets: Hyderabad is well-positioned to serve both domestic and international markets, with easy access to major markets in Asia, Europe, and North America.
Sure, here are some recent news articles about Hyderabad pharmaceutical companies:
- Aurobindo Pharma: In January 2023, Aurobindo Pharma announced that it had received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Lenvatinib Capsules, used in the treatment of thyroid cancer.
- Dr. Reddy’s Laboratories: In February 2022, Dr. Reddy’s Laboratories announced that it had launched its generic version of Tricor tablets, used to treat high cholesterol, in the US market.
- Hetero Drugs: In December 2021, Hetero Drugs announced that it had received Emergency Use Authorization (EUA) from the Indian drug regulator for its COVID-19 treatment drug, Sotrovimab.
- Divis Laboratories: In August 2021, Divis Laboratories announced that it had received a warning letter from the US FDA regarding its Visakhapatnam facility over concerns of data integrity and data manipulation.
- Granules India: In May 2021, Granules India announced that it had received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Duloxetine Delayed-Release Capsules, used in the treatment of depression and anxiety.